Primary breast lymphoma (PBL) is considered a rare clinical entity forming about 0.4%-0.5% of all breast tumors.In this report we have presented a case of PBL in a 56-year-old female complaining of a mass in the upper medial quadrant of the breast.PBL suspicion of our case was made by breast radiology and the sure diagnosis was reached by the immunohistochemistry results; CD (cluster of differentiation) 20: was diffusely positive; Pan-CK (pan-cytokeratin): was diffusely negative in tumor cells. Hence, the case was finally diagnosed as a primary breast a primary breast diffuse large B-cell non-Hodgkin's lymphoma of lymphoma.The management and outcome of PBL and carcinoma are totally different. Accurate diagnosis of PBL by true cut needle biopsy and immunocytochemistry is important to avoid unnecessary mastectomies.
Serous ovarian carcinoma (SOC) is an ovarian cancer with a high fatality rate. Therefore, a lot of researchers have tried to identify novel prognostic biomarkers which might improve the patient prognosis. The aims of the study were to detect the tissue protein expression of Beclin-1 in addition to HIF-1α in SOC patients, to evaluate the relationship between their expression, the clinicopathological parameters, patients' prognosis, and the relation to chemotherapy resistance in SOC. We evaluated the expression of Beclin-1 in addition to HIF-1α in 60 patients with SOC using immunohistochemistry, followed all patients for about 36 months, analyzed associations between both markers' expression, clinicopathological data, and patients' prognosis. Beclin-1 expression was related to low grade (p = 0.002), early SOC stage, absence of peritoneal spread (p = 0.006), and absence of lymph nodes, and distant metastases (p = 0.004 and < 0.001 respectively), while HIF-1α expression was associated with higher grade and stage (p = 0.007), and presence of nodal and distant metastases (p < 0.001 and = 0.012 respectively). High Beclin-1 expression and low HIF-1α expression were positively associated with good response to chemotherapy (p = 0.047 and p = 0.022 respectively), a lower recurrence rate after successful therapy (p = 0.006 and < 0.001 respectively), and increased three-year recurrence-free and overall survival rates (p < 0.001). In SOC patients; Beclin-1 is a good prognostic marker, while HIF-1α is a poor prognostic marker.
Introduction: Sulfiredoxin (Srx), which is an endogenous antioxidant substance which could, regulate the signaling pathways of reactive oxygen species. Nuclear factor erythroid 2-related factor 2 (Nrf2) is Cap-N-collar (CNC) transcription factors family member that have essential roles in regulation of antioxidant response. The transcription factor PROX1 is a transcription factor and a key regulatory protein in cancer development. Aim of the study: To analyze levels of tissue expression of Srx, Nrf2, and PROX1 in gastric cancer and adjacent non-neoplastic gastric mucosa to clarify the relationship between their expression levels, clinical, pathological parameters and patients' outcome. The results might lead to discovering novel targeted therapies to gastric cancers. Material and methods: We included 70 paraffin-embedded samples: 50 specimens from gastric carcinomas and 20 specimens from adjacent non-neoplastic gastric mucosa. All samples are stained with Srx, Nrf2, and PROX1 using immunohistochemistry, correlated their expression with clinicopathological and prognostic parameters of patients. Results: High levels of Srx and Nrf2 expression were positively associated with higher cancer grade (p = 0.006, 0.031 respectively), advanced stage (p < 0.001, 0.02 respectively), higher incidence of distant metastases (p = 0.029, 0.03 respectively) and dismal outcome (p < 0.001). High levels of PROX1 expression were associated with lower cancer grade (p = 0.005), absence of lymph nodes metastases (p = 0.023), early stage (p = 0.003), absence of relapse (p = 0.004), and favorable outcome (p < 0.001). Conclusions: Srx and Nrf2 expression increase gastric cancer invasiveness, suggesting their utility as poor prognostic markers, but PROX1 serves as a favorable prognostic marker of gastric cancer patients.
Background. Detection of novel predictive markers for early detection of lymph nodes metastases in cervical cancer is very important. Disturbed NR2F6 expression was found in many cancers playing different roles according to cancer type. LOXL2 was incriminated in cancer progression and unfavorable survival in many cancer types. Decreased DMBT1 expression was found in many cancers during their progression. Aim of the present work was to assess expression of NR2F6, LOXL2 and DMBT1 in cervical cancer tissues using immunohistochemistry then correlating their expression with grade and stage of the tumor, occurrence of lymph nodes and distant metastases in addition to evaluating their prognostic roles. Materials and methods. We assessed the expression of NR2F6, LOXL2 and DMBT1 in samples retrieved from sixty two cervical cancer patients in cancer tissues and corresponding adjacent normal tissues and we correlated markers expression with clinical data, pathological findings and patients' prognosis. Results. High expression of NR2F6, LOXL2 and low expression of DMBT1 was up-regulated in cervical cancer tissues more than in adjacent non-neoplastic cervical tissues and was associated with high grade (p = 0.005), lymphovascular space involvement, advanced FIGO stage, resistance to chemotherapy, tumor recurrence, and shorter survival rates (p < 0.001). Conclusions. Up regulation of NR2F6, LOXL2 and down regulation of DMBT1 were associated with unfavorable pathological parameters, bad clinical findings and dismal outcome of cervical cancer patients.
SOMMARIOContesto. La rilevazione di nuovi marcatori predittivi per la diagnosi precoce delle metastasi linfonodali nel cancro cervicale è molto importante. L'espressione distorta di NR2F6 è stata trovata in molti tumori che svolgono ruoli diversi a seconda del tipo di cancro. LOXL2 è stato incriminato nella progressione del cancro e nella sopravvivenza sfavorevole in molti tipi di cancro. La diminuzione dell'espressione di DMBT1 è stata trovata in molti tumori durante la loro progressione. Lo scopo del presente lavoro era valutare l'espressione di NR2F6, LOXL2 e DMBT1 nei tessuti del cancro cervicale mediante immunoistochimica, quindi correlando la loro espressione con il grado e lo stadio del tumore, la presenza di linfonodi e metastasi a distanza, oltre a valutare i loro ruoli prognostici. Materiali e metodi. Abbiamo valutato l'espressione di NR2F6, LOXL2 e DMBT1 in campioni prelevati da sessantadue pazienti con cancro cervicale nei tessuti tumorali e nei corrispondenti tessuti normali adiacenti e abbiamo correlato l'espressione dei marcatori con i dati clinici, i risultati patologici e la prognosi dei pazienti. Risultati. L'alta espressione di NR2F6, LOXL2 e la bassa espressione di DMBT1 erano sovraregolate nei tessuti del cancro cervicale più che nei tessuti cervicali adiacenti non neoplastici ed erano associate ad alto grado (p = 0,005), coinvolgimento dello spazio linfovascolare, stadio FIGO avanzato, resistenza a chemioterapia, recidiva del tumore e tassi di sopravvivenza pi...
Context
PD-L1 is an inhibitory ligand that functions as an essential immune checkpoint. FOXP-1 is a member of the FOXP family. STAT-3 plays a critical role in regulation of cell proliferation and survival. The detailed expression of the three markers together in DLBCL tissues and their prognostic value in patients with DLBCL were not fully investigated.
Aim was to assess the expression of PD-L1, FOXP-1 and STAT-3 in diffuse large B-cell lymphoma (DLBCL) and to correlate their expression with the pathological findings, prognostic parameters and clinical implications of patients.
Methods
PD-L1, FOXP-1 and STAT-3 were assessed in DLBCL tissues derived from 50 patients using immunohistochemistry. Patients were followed up for 3 years for response to therapy progression, recurrence and survival.
Results
High PD-L1 expression was associated with bone marrow involvement (p = 0.004), extra-nodal involvement (p = 0.006) and advanced stage (p = 0.003). High FOXP-1 expression was associated with presence of bone marrow involvement and high risk group (p < 0.001). High STAT-3 expression was associated with older age of the patient (p < 0.001), presence of bone marrow involvement (p = 0.002), extra-nodal involvement (p = 0.009), and high risk group (p = 0.005). High expression of PD-L1, FOXP-1 and STAT-3 was related to poor response to therapy, poor OS rate and RFS rates (p < 0.001).
Conclusion
High expression of PD-L1, FOXP-1 and STAT-3 was related poor prognosis in DLBCL patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.